RBC Capital analyst Michael Carroll maintained a Hold rating on Medical Properties (MPW – Research Report) on March 7 and set a price target of ...

RBC Capital analyst Leonid Timashev maintained a Buy rating on Edgewise Therapeutics (EWTX – Research Report) today and set a price target of $56.00. The company’s shares closed last Friday at $28.01.

Fintel reports that on March 7, 2025, RBC Capital initiated coverage of Vertiv Holdings (NYSE:VRT) with a Outperform ...

Fintel reports that on March 7, 2025, RBC Capital initiated coverage of GH Research (NasdaqGM:GHRS) with a Outperform ...

Investing.com -- Galderma Group AG has been downgraded by RBC Capital Markets to "sector perform" from "outperform," ...

RBC Capital raised the firm’s price target on AdaptHealth (AHCO) to $14 from $11 and keeps an Outperform rating on the shares ...

Popular, Inc. (NASDAQ: BPOP) announced today that it will participate in the upcoming RBC Capital Markets Global Financial ...

RBC Capital Markets Global Financial Institutions Conference Transcript March 5, 2025 11:20 AM ETCompany ParticipantsJohn Stern ...

In the second quarter of last year, RBC closed its deal to takeover HSBC Bank Canada, which was Canada’s seventh-largest ...

Toronto-Dominion Bank beat estimates on better-than-expected wealth-management and capital-markets results, capping off an ...

Three of Canada's big five lenders - Royal Bank of Canada, TD Bank and CIBC - on Thursday beat analyst expectations for ...